BEGIN:VCALENDAR VERSION:2.0 PRODID:-//The BioCalendar - ECPv6.15.20//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-ORIGINAL-URL:https://thebiocalendar.com X-WR-CALDESC:Events for The BioCalendar REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:America/Los_Angeles BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20250309T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20251102T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20260308T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20261101T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20270314T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20271107T090000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;VALUE=DATE:20260504 DTEND;VALUE=DATE:20260506 DTSTAMP:20260424T014141 CREATED:20251206T101622Z LAST-MODIFIED:20260125T043207Z UID:9626-1777852800-1778025599@thebiocalendar.com SUMMARY:TRI-CON 2026 DESCRIPTION:Join us for an exclusive gathering of senior-level investors\, pharma executives\, entrepreneurs\, research thought leaders\, and innovators at the 33rd Annual TRI-CON. Connect with investors and partners at intimate networking sessions; gain strategic insights on funding activities\, business development\, and innovation strategies in diagnostics\, precision medicine\, and AI from industry-led panels; and hear candid perspectives and business recommendations from key opinion leaders during dynamic fireside chats. Building on a 30+ track record\, TRI-CON is positioned as the premier meeting place for key stakeholders to foster meaningful connections\, acquire valuable strategic insights\, and drive innovation and collaboration. Returning to San Francisco in 2026! URL:https://thebiocalendar.com/event/tri-con-2026/ LOCATION:San Francisco\, CA\, San Francisco\, CA\, United States CATEGORIES:Featured,Investor,Networking,Partnering,Presentation,Summit ATTACH;FMTTYPE=image/jpeg:https://thebiocalendar.com/wp-content/uploads/2026/01/tric-scaled.jpg END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260504 DTEND;VALUE=DATE:20260508 DTSTAMP:20260424T014141 CREATED:20260327T140336Z LAST-MODIFIED:20260327T140336Z UID:10105-1777852800-1778198399@thebiocalendar.com SUMMARY:SynBioBeta 2026 DESCRIPTION:Join our SynBioBeta community for three days of high-signal talks\, curated 1:1 meetings\, real partnering\, and hands-on exposure at the frontier of biology and technology. \nGo deep on AI-driven biology and therapeutics. You’ll also get up to speed on sustainable biomanufacturing of chemicals\, materials\, food\, and consumer products\, and discover applications of biology that you never thought possible. \nThis is where global builders\, backers\, and scouts have mind-blowing conversations and find their next moves. URL:https://thebiocalendar.com/event/synbiobeta-2026/ LOCATION:San Jose\, San Jose\, CA\, United States CATEGORIES:Summit END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260504T110000 DTEND;TZID=America/Los_Angeles:20260504T120000 DTSTAMP:20260424T014141 CREATED:20260326T132035Z LAST-MODIFIED:20260326T132035Z UID:10076-1777892400-1777896000@thebiocalendar.com SUMMARY:The Shift to High Concentration mAbs: 3 Critical UF/DF Challenges and How to Solve Them DESCRIPTION:A practical look at overcoming viscosity\, fouling\, and aggregation with modern TFF platforms. \nAs monoclonal antibody therapies continue to evolve\, the industry is rapidly shifting from traditional mAb formulations to high‑concentration mAbs to enable subcutaneous delivery\, improve patient convenience\, and support next‑generation therapeutics. While this shift delivers clear clinical benefits\, it also introduces new risks and complexities particularly during ultrafiltration and diafiltration (UF/DF). \nIn this webinar\, we’ll examine how increasing protein concentration fundamentally changes UF/DF behavior—and why legacy approaches often struggle as viscosity rises and operating windows narrow. We’ll break down the three most critical UF/DF challenges associated with high‑concentration mAbs and discuss practical strategies to address them using modern TFF platforms. \nKey topics include:\n – Why the industry is shifting toward high‑concentration mAbs—and what this means for downstream bioprocessing\n – The three critical UF/DF challenges at high concentration:\n ~ Managing viscosity and its impact on flux\, pressure\, and process control\n ~ Preventing fouling and polarization that limit performance and scalability\n ~ Reducing aggregation risk during concentration and diafiltration\n – How modern\, automated TFF system design can help mitigate these risks\n – What to consider when adapting UF/DF strategies for development\, scale‑up\, and manufacturing \nWhether you are developing next‑generation mAbs or scaling existing programs to higher concentrations\, this session will provide practical insights to help you build more robust\, repeatable UF/DF processes for the high‑concentration era. URL:https://thebiocalendar.com/event/the-shift-to-high-concentration-mabs-3-critical-uf-df-challenges-and-how-to-solve-them/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/03/05-04-26-Repligen-Linkedin-1280x720-1.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20260504T130000 DTEND;TZID=America/Los_Angeles:20260504T140000 DTSTAMP:20260424T014141 CREATED:20260408T190440Z LAST-MODIFIED:20260408T190440Z UID:10172-1777899600-1777903200@thebiocalendar.com SUMMARY:A Novel Cell Selective Lentiviral Platform for in vivo CAR-T Engineering DESCRIPTION:Selective gene delivery to defined cell populations using targeted lentiviral vectors (LVV) represents a promising strategy for next‑generation immunotherapies such as chimeric antigen receptor (CAR) T‑cell therapy. While conventional CAR-T cell manufacturing requires multiple ex vivo manipulation steps up to two weeks\, targeted LVVs can enable a short ex vivo manufacturing process or direct in vivo generation of functional CAR-T cells with substantial lower complexity and cost\, improving accessibility to the therapy. \nWe have developed a novel paramyxovirus (PV)‑pseudotyped LVV platform designed for efficient gene transfer into non‑activated T cells ex vivo and in vivo. In this system\, viral binding and fusion are mediated by modified hemagglutinin (H) and fusion (F) glycoproteins respectively. Mutation of H abolishes natural tropism\, while retargeting is achieved by fusing cell‑specific single‑chain variable fragments (scFvs) or heavy‑chain variable domains (VHHs)\, enabling targeted transduction. \nUsing our high titer packaging cell line and an optimized transfection process\, we produced CD4‑\, CD8‑\, and pan‑T‑cell–specific LVV\, which efficiently generated CAR-T cells in vitro and in vivo in a PBMC-transplanted NSG mouse model. Importantly\, these CAR-T cells led to robust tumor lysis in vitro and rapid tumor B-cell depletion in vivo\, highlighting the clinical feasibility of this approach. \nIn summary\, our optimized targeted LVV platform enables selective and rapid generation of defined CAR-T cell subsets\, providing a foundation for safe\, cost-effective and accessible CAR-T cell therapies. URL:https://thebiocalendar.com/event/a-novel-cell-selective-lentiviral-platform-for-in-vivo-car-t-engineering/ ATTACH;FMTTYPE=image/png:https://thebiocalendar.com/wp-content/uploads/2026/04/05-04-26-Miltenyi-LinkedIn-1280x720-1.png END:VEVENT END:VCALENDAR